Colette Knight, MD
Endocrinology, Diabetes & Metabolism · Hackensack, NJNPI 1063612596
Payments from drug & device makers
Across 313 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$837
- Medtronic$371
- AstraZeneca$342
- Abbott$296
- Boehringer Ingelheim$253
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,22298%
- Education$832%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 70 | $1,055 |
| Lilly USA, LLC | 67 | $837 |
| Medtronic(2 entities) | 11 | $371 |
| AstraZeneca(2 entities) | 17 | $342 |
| Abbott | 15 | $296 |
| Boehringer Ingelheim | 16 | $253 |
| Amgen | 15 | $253 |
| Sanofi-aventis U.S. LLC | 15 | $238 |
| Insulet Corporation | 9 | $217 |
| Corcept Therapeutics | 10 | $208 |
| Xeris Pharmaceuticals, Inc. | 12 | $200 |
| Tandem Diabetes Care, Inc. | 11 | $196 |
| Mannkind Corporation | 9 | $156 |
| Dexcom, Inc. | 7 | $146 |
| Cequr Corporation | 5 | $144 |
| Merck | 7 | $102 |
| Ascendis Pharma Endocrinology Inc | 3 | $51 |
| Radius Health, Inc. | 2 | $33 |
| Neurocrine Biosciences, Inc. | 2 | $33 |
| Amneal Pharmaceuticals LLC | 2 | $30 |
| BETA Bionics, Inc. | 1 | $28 |
| Zealand Pharma US, Inc. | 1 | $21 |
| Alvogen Inc | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $18 |
| AbbVie | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Amphastar Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$5,305 in reported general payments places this provider in the 70th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 203 | $245,502 |
| MounjaroTirzepatide | 78 | $94,686 |
| JardianceEmpagliflozin | 48 | $66,891 |
| TrulicityDulaglutide | 39 | $65,282 |
| ProliaDenosumab | 23 | $40,359 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 27 | $32,979 |
| Teriparatide | 13 | $31,239 |
| RybelsusSemaglutide | 15 | $30,626 |
| TymlosAbaloparatide | 11 | $28,548 |
| Humalog Kwikpen U-200Insulin Lispro | 31 | $26,878 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 65 | $24,534 |
| Bydureon BciseExenatide Microspheres | 25 | $20,858 |
| FarxigaDapagliflozin Propanediol | 13 | $20,496 |
| TradjentaLinagliptin | 22 | $18,048 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $17,536 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,055 | $280,811234 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $837 | $163,953133 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $253 | $93,76181 claims |
| AmgenProlia | $253 | $40,35923 claims |
| Alvogen IncTeriparatide | $19 | $31,23913 claims |
| Radius Health, Inc.Tymlos | $33 | $28,54811 claims |
| AstraZenecaFarxiga | $342 | $20,49613 claims |
| MerckJanuvia | $102 | $17,24514 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $30 | $2,739247 claims |
| AbbVieSynthroid | $16 | $1,71720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Hackensack
- Natalia AnchipolovskyHackensack$40K
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Taher ModarressiPennington$414K
- Navtika DesaiHillsborough$408K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.